For more information please visit: About Nuclear Diagnostic Products, Inc. Triad’s network of specialized facilities provide the products used by hospitals and nuclear medicine operators to help diagnose and treat patients, primarily those with cardiac and cancer concerns. The company’s national network of more than 54 locations serves 4 million patients each year, making Triad Isotopes the nation’s second-largest radiopharmaceutical provider. is a nationwide nuclear pharmacy company headquartered in Orlando, Fla. For full prescribing information for NETSPOT TM please refer to. The kit has been designated as an orphan drug by the EMA and the FDA. NETSPOT TM is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography (“PET“). We believe in the potential of NETSPOT TM to improve the accuracy of diagnoses of NETs and our goal is to provide access for as many patients as possible.” We look forward to working closely with all of our partners and expanding the potential market reach of NETSPOT TM. We believe that Triad and NDP both bring significant capabilities to our network, including Triad’s broad footprint and extensive experience with neuroendocrine tumor products, and NDP’s strong position and customer focus in the Northeast region of the country. Stefano Buono, Chief Executive Officer of AAA said, “With the addition of these new supply chain relationships, we are well positioned to initiate the launch of NETSPOT TM. NDP’s experience and expertise in customer service will support NETSPOT™ distribution, one patient at a time.” is committed and looking forward to serving patients and nuclear medicine departments with the preparation and delivery of NETSPOT™. Wayne Wong, Vice President of Product Development for NDP noted, “Nuclear Diagnostic Products, Inc. With our large pharmacy network, we continue to provide world renowned technical expertise in the compounding and delivery of radiopharmaceuticals.” Marc Pfefferle, Chief Executive Officer of Triad stated, “We are excited about this opportunity and the ability to provide the benefits of NETSPOT™ to our customers. The addition of these partnerships completes the foundation of a robust nationwide supply chain that now includes four radiopharmacy networks. Triad and NDP will each prepare and deliver NETSPOT TM patient doses to advanced medical imaging sites in selected metropolitan areas. The product has received orphan drug designation from the FDA. Food and Drug Administration (“FDA”) for the preparation of Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors (“NETs”) in adult and pediatric patients using Positron Emission Tomography (“PET“). NETSPOT TM (formerly known as Somakit-TATE) is a patented kit recently approved by the U.S. (“UPPI”), to supply gallium 68 (“Ga 68”) dotatate doses prepared with a novel kit to U.S. (“NDP”), a company with three radiopharmacies in the Northeast and a member of United Pharmacy Partners Inc. supply chain for NETSPOT TM with the addition of two radiopharmacy networks, Triad Isotopes, Inc., the second largest radiopharmaceutical company in the United States, and Nuclear Diagnostic Products, Inc. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it has further strengthened its U.S. Check with your local Jubilant Radiopharmacies Division's pharmacy for details regarding weekend and after-hours orders.SAINT-GENIS-POUILLY, France, J(GLOBE NEWSWIRE) - Advanced Accelerator Applications S.A.To request changes to existing prescription orders, please call the specific pharmacy that received the online order.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |